[DOI] [PMC free article] [PubMed] [Google Scholar] 8.Sikiric P., Seiwerth S., Rucman R., Turkovic B., Rokotov D.S., Brcic L., Sever M., Klicek R., Radic B., Drmic D., et al
In the Retatrutide diabetes trial, gastrointestinal adverse events appeared in roughly 35 percent of treated participants, the same family of effects seen across this drug class, and no severe low-blood-sugar episodes or deaths were reported
It plays a key role in red blood cell production, DNA synthesis, and nerve function
No other orally administered peptide or peptidomimetic commonly discussed in the research community has demonstrated comparable, reproducible IGF-1 elevation in human studies